Zwingenberg, Germany

Dave Trupti

This inventor holds 1 USPTO granted patent, plus 1 CIPO patent and 1 EPO patent. Top assignee: Evonik Rohm Gmbh. Active years: 2013.




Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 6(Granted Patents)


Company Filing History:


Years Active: 2013

Loading Chart...
Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovative Contributions of Dave Trupti

Introduction

Dave Trupti is a notable inventor based in Zwingenberg, Germany. He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of multiparticulate forms of administration. His work focuses on enhancing the delivery of nucleic acid-containing active ingredients.

Latest Patents

Trupti holds a patent for a multiparticulate form of administration, which comprises nucleic acid-containing mucoadhesive active ingredients. The patent describes an oral, multiparticulate form of administration that includes pellets sized between 50 to 2500 micrometers. The formulation consists of an inner matrix layer containing nanoparticles with a nucleic acid active ingredient embedded in a mucoadhesive polymer matrix, along with an outer film coating made of an anionic polymer or copolymer, optionally combined with conventional pharmaceutical adjuvants.

Career Highlights

Throughout his career, Dave Trupti has worked with various companies, including Evonik Rohm GmbH. His experience in the pharmaceutical industry has allowed him to develop innovative solutions that address complex challenges in drug delivery systems.

Collaborations

Trupti has collaborated with notable professionals in his field, including Rosario Lizio and Hans-Ulrich Petereit. These collaborations have contributed to the advancement of his research and the successful development of his inventions.

Conclusion

Dave Trupti's innovative work in the field of pharmaceutical formulations has led to significant advancements in drug delivery systems. His contributions continue to impact the industry positively.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…